Clinical and etiological profile of unprovoked thrombosis in young patients admitted at a tertiary care hospital


  • Nadeem Ahmad Department of Internal Medicine, GMC Srinagar Kashmir, India
  • Nihida Akhter Department of Gynaecology and Obstetrics, LD hospital, Kashmir, India
  • Tufail Ahmad Sheikh Department of Anesthesiology and Critical Care SMHS Hospital Sringar, Kashmir, India



Deep venous thrombosis, Factor V Leiden, Thrombophilias, Thromboembolism, Warfarin


Background: It is now possible to identify acquired and hereditary risk factors in a substantial percentage of patients presenting with a venous thrombotic event. The objective of the study was to study the clinical and etiological profile of patients with unprovoked thrombosis in young patients.

Methods: Twenty-one patients 09 males (42.8%) and 12 females (57.14%) with a mean age of 29.67±5.21 were studied, who presented with unprovoked thrombosis.

Results: Among 21 patients studied most common presentation was deep venous thrombosis of lower limbs (38.09%) followed by recurrent abortions with deep venous thrombosis (14.28%) and cerebellar infarction (14.28%). In etiological profile, the most common thrombophilla was factor V Leiden mutation (28.57%) followed by antiphospholipid antibody syndrome (23.8%), protein C deficiency (19.04%), methylene tetrahydrofolate reductase (9.52%) and antithrombin, prothrombin gene mutation, hyperhomocystenemia and janus kinase 2 mutations (4.76%). Among 6 patients of factor V Leiden mutation 3 presented with deep venous thrombosis of lower limbs, 1 patient each with middle cerebral artery infarct, juglar vein thrombosis and subclavian vein thrombosis respectively.

Conclusions: Factor V Leiden mutation is the most common inherited thrombophillias which has been "substantiated from various studies.


De-Sweet M. Thromboembolism. In:De-Sweet M, Medical Disorders in Obstetric Practice, 4th edition. Blackwell Science, UK; 2002:100-24.

Bauduer F, Lacombe D. Leiden FV. Prothrombin 20210A, methylenetetrahydrofolate reductase 677T, and population genetics. Molecular genetics and metabolism. 2005;86(1):91-9.

Kovalevsky G, Gracia CR, Berlin JA, Sammel MD, Barnhart KT. Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss: a meta-analysis. Archives of internal medicine. 2004;164(5):558-63.

Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369(6475):64-7.

Koster T, Vandenbroucke JP, Rosendaal FR, de Ronde H, Briët E, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. The Lancet. 1993;342(8886-8887):1503-6.

Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 39-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88(10):3698-703.

Segal JB, Brotman DJ, Necochea AJ, Emadi A, Samal L, Wilson LM, et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. JAMA. 2009;301(23):2472-85.

De Stefano V, Rossi E, Paciaroni K, Leone G. Screening for inherited thrombophilia: indications and therapeutic implications. haematologica. 2002;87(10):1095-108.

White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(23 suppl 1):1-4.

Dahlbäck B. Factor V. Gene mutation causing inherited resistance to activated protein C as a basis for venous thromboembolism. Journal of internal medicine. 1995;237(3):221-7.

Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 332:912:1995.

Markus HS, Zhang Y, Jeffery S. Screening for the factor-V Arg 506 Gln mutation in patients with TIA and stroke. Cerebrovasc Dis. 1996;6:360.

Albucher JF, Guiraud Chaumeil B, Chollet F, Cadroy Y, Sie P. Frequency of resistance to activated protein C due to factor V mutation in young patients with ischemic stroke. Stroke. 1996;27:766.

De Lucia D, Cerbone AM, Belli A, Di Mauro C, Renis V, Conte MM. et al: Resistance to activated protein C in adults with a history of juvenile transient ischaemic attacks. Thromb Haemost. 1996;76:627.

Landi G, Cella E, Martinelli I, Tagliabue L, Mannucci PM, Zerbi D. Arg506Gln factor V mutation and cerebral ischemia in the young. Stroke. 1996;27:1697.

Horne MK, McCloskey DJ, Leiden FV. as a common genetic risk factor for venous thromboembolism. J Nurs Scholarsh. 2006;38(1):19-25.

Hughes G, Khamashta MA. Hughes Syndrome: Highways and Byways. Springer; 2013.

Rand JH. Antiphospholipid antibody syndrome: new insights on thrombogenic mechanisms. The American journal of the medical sciences. 1998;316(2):142-51.

Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. "Deficiency of protein C in congenital thrombotic disease". J. Clin. Invest. 1981;68(5): 1370-3.

Khan S, Dickerman JD. Hereditary thrombophilia. Thrombosis J. 2006;4(1):15.




How to Cite

Ahmad, N., Akhter, N., & Sheikh, T. A. (2017). Clinical and etiological profile of unprovoked thrombosis in young patients admitted at a tertiary care hospital. International Journal of Research in Medical Sciences, 5(10), 4595–4599.



Original Research Articles